ID   UG5LN GAL4-hMR
AC   CVCL_E7IU
WW   Provider; Inserm Transfert; RT00626; https://technology-offers.inserm-transfert.com/offer/ug5ln-gal4-hmr-cell-line/
CC   Population: Caucasian.
CC   Characteristics: Transfected with a (GAL4RE)5-betaGlobin-Luc-SV40-Neo construct where expression of the luciferase gene is driven by a pentamer of yeast activator GAL4-binding sites in front of beta-globin promoter and a pSG5-GAL4-hMR-puroR construct containing the GAL4 DNA-binding domain fused to the ligand-binding domain of human NR3C2/MR (Inserm Transfert=RT00626).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:7979; NR3C2 (Note=Ligand-binding domain).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P04386; Yeast GAL4 (Note=With p.Ile148_Glu881del = DNA-binding domain).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E7IT ! UG5LN
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//